Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Impel NeuroPharma launches Reroute Migraine Relief initiative » 08:08
05/18/21
05/18
08:08
05/18/21
08:08
IMPL

Impel NeuroPharma

$13.80 /

+0.19 (+1.40%)

Impel NeuroPharma…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IMPL Impel NeuroPharma
$13.80 /

+0.19 (+1.40%)

07:47 Today Wedbush
Wedbush bullish on Impel NeuroPharma, initiates with an Outperform
07:00 Today Wedbush
Impel NeuroPharma initiated with an Outperform at Wedbush
06:32 Today Guggenheim
Impel NeuroPharma initiated with a Buy at Guggenheim
  • 23
    Apr
Initiation
Wedbush bullish on Impel NeuroPharma, initiates with an Outperform » 07:47
05/18/21
05/18
07:47
05/18/21
07:47
IMPL

Impel NeuroPharma

$13.80 /

+0.19 (+1.40%)

As previously reported,…

As previously reported, Wedbush analyst Laura Chico initiated coverage of Impel NeuroPharma with an Outperform rating and $21 price target. The analyst notes that drug delivery to the CNS represents a perennial problem, driving both safety and efficacy profiles. NeuroPharma's proprietary Precision Olfactory Delivery system seeks to overcome these challenges by delivering drugs to the upper nasal cavity, bypassing the blood-brain barrier, Chico says. Her prior Key Opinion Leaders conversations indicate favorable perceptions of DHE, with a desire for a more patient-friendly format. The analyst sees the company's Trudhesa fulfilling this profile and the 9/6/21 PDUFA as providing an important catalyst. Additionally, Chico views NeuroPharma's efforts aided by both physicians' underlying knowledge of DHE and the company's Phase 3 results.

ShowHide Related Items >><<
IMPL Impel NeuroPharma
$13.80 /

+0.19 (+1.40%)

07:00 Today Wedbush
Impel NeuroPharma initiated with an Outperform at Wedbush
06:32 Today Guggenheim
Impel NeuroPharma initiated with a Buy at Guggenheim
  • 23
    Apr
Initiation
Impel NeuroPharma initiated with an Outperform at Wedbush » 07:00
05/18/21
05/18
07:00
05/18/21
07:00
IMPL

Impel NeuroPharma

$13.80 /

+0.19 (+1.40%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico initiated coverage of Impel NeuroPharma with an Outperform rating and $21 price target.

ShowHide Related Items >><<
IMPL Impel NeuroPharma
$13.80 /

+0.19 (+1.40%)

06:32 Today Guggenheim
Impel NeuroPharma initiated with a Buy at Guggenheim
  • 23
    Apr
Initiation
Impel NeuroPharma initiated with a Buy at Guggenheim » 06:32
05/18/21
05/18
06:32
05/18/21
06:32
IMPL

Impel NeuroPharma

$13.80 /

+0.19 (+1.40%)

Guggenheim analyst Dana…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
  • 23
    Apr
Over a week ago
Syndicate
Impel NeuroPharma opens at $15.31, IPO priced at $15 per share » 11:50
04/23/21
04/23
11:50
04/23/21
11:50
IMPL

Impel NeuroPharma

/

+

Impel NeuroPharma (IMPL)…

Impel NeuroPharma (IMPL) priced 5.33M shares at $15.00. The deal priced at midpoint of $14.00-$16.00 range. Cowen and Guggenheim are acting as joint book running managers for the offering. Impel NeuroPharma is a late-stage pharmaceutical company focused on advancing its product candidate pipeline - which includes TRUDHESA for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease - paired with its proprietary Precision Olfactory Delivery system.

ShowHide Related Items >><<
  • 23
    Apr
Syndicate
Impel NeuroPharma 5.33M share IPO priced at $15.00 » 18:51
04/22/21
04/22
18:51
04/22/21
18:51
IMPL

Impel NeuroPharma

/

+

The deal priced at…

The deal priced at midpoint of $14.00-$16.00 range. Cowen and Guggenheim are acting as joint book running managers for the offering.

ShowHide Related Items >><<
  • 23
    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.